7.87
price up icon0.25%   0.02
after-market 시간 외 거래: 7.87
loading
전일 마감가:
$7.85
열려 있는:
$7.83
하루 거래량:
1.65M
Relative Volume:
0.94
시가총액:
$543.15M
수익:
-
순이익/손실:
$-30.04M
주가수익비율:
-4.981
EPS:
-1.58
순현금흐름:
$-27.38M
1주 성능:
+0.25%
1개월 성능:
+360.23%
6개월 성능:
+435.37%
1년 성능:
+249.78%
1일 변동 폭
Value
$7.8112
$7.92
1주일 범위
Value
$7.801
$7.92
52주 변동 폭
Value
$0.8301
$8.20

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name
명칭
Regulus Therapeutics Inc
Name
전화
858-202-6300
Name
주소
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Name
직원
34
Name
트위터
@regulusrx
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
RGLS's Discussions on Twitter

RGLS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RGLS
Regulus Therapeutics Inc
7.87 543.15M 0 -30.04M -27.38M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-27 업그레이드 Wells Fargo Equal Weight → Overweight
2024-08-02 개시 Oppenheimer Outperform
2024-03-18 개시 Leerink Partners Outperform
2018-03-28 개시 B. Riley FBR, Inc. Neutral
2018-01-05 개시 Leerink Partners Outperform
2017-06-13 재확인 Chardan Capital Markets Buy
2017-03-06 재확인 Wedbush Outperform
2017-01-30 다운그레이드 Needham Buy → Hold
2017-01-30 다운그레이드 Wells Fargo Outperform → Market Perform
2016-12-07 재확인 Chardan Capital Markets Buy
2016-11-02 재확인 Needham Buy
2016-07-25 재확인 Chardan Capital Markets Buy
2016-06-28 재확인 Chardan Capital Markets Buy
2016-06-28 재확인 FBR Capital Outperform
2016-06-28 재확인 Needham Buy
2016-06-07 재확인 Chardan Capital Markets Buy
2016-04-13 개시 Chardan Capital Markets Buy
2015-12-04 개시 Wells Fargo Outperform
2015-06-09 개시 Guggenheim Buy
2015-04-21 재개 FBR Capital Outperform
2014-11-24 개시 Deutsche Bank Buy
2014-08-07 재확인 FBR Capital Outperform
2013-08-14 재확인 Needham Buy
모두보기

Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스

pulisher
May 09, 2025

Regulus Therapeutics to be Acquired by Novartis - TipRanks

May 09, 2025
pulisher
May 08, 2025

Regulus: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025
pulisher
May 08, 2025

Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - PR Newswire

May 08, 2025
pulisher
May 06, 2025

Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN

May 06, 2025
pulisher
May 06, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com

May 06, 2025
pulisher
May 04, 2025

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire

May 04, 2025
pulisher
May 03, 2025

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus

May 03, 2025
pulisher
May 03, 2025

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN

May 03, 2025
pulisher
May 02, 2025

Taxation With Representation: Goodwin, Haynes Boone - Law360

May 02, 2025
pulisher
May 01, 2025

Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - San Diego Union-Tribune

May 01, 2025
pulisher
May 01, 2025

Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga

May 01, 2025
pulisher
May 01, 2025

Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus

May 01, 2025
pulisher
May 01, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 01, 2025
pulisher
May 01, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancor - Morningstar

May 01, 2025
pulisher
May 01, 2025

Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare

May 01, 2025
pulisher
May 01, 2025

Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN

May 01, 2025
pulisher
May 01, 2025

Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers

May 01, 2025
pulisher
May 01, 2025

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc.RGLS - The Malaysian Reserve

May 01, 2025
pulisher
May 01, 2025

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus

May 01, 2025
pulisher
Apr 30, 2025

Regulus (RGLS) Downgraded After Acquisition Agreement with Novar - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Regulus Therapeutics Inc (RGLS): Shares Soar 137% on Acquisition News - Wealth Daily

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis Gains Further Renal Territory With Regulus Acquisition - insights.citeline.com

Apr 30, 2025
pulisher
Apr 30, 2025

Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (RGLS) - Seeking Alpha

Apr 30, 2025
pulisher
Apr 30, 2025

Regulus Therapeutics stock soars on acquisition deal with Novartis By Investing.com - Investing.com Nigeria

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize

Apr 30, 2025
pulisher
Apr 30, 2025

Wells Fargo Downgrades Regulus Therapeutics to Equalweight From Overweight, $9 Price Target - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

India’s Competition Commission Clears J&K Bank in Antitrust Case - PYMNTS.com

Apr 30, 2025
pulisher
Apr 30, 2025

Top Midday Gainers - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring - RagingBull

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to buy Regulus Therapeutics for up to $1.7 billion - MSN

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive

Apr 30, 2025
pulisher
Apr 30, 2025

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal - Reuters

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to Acquire Regulus Therapeutics in Potential $1.7B Deal - Contract Pharma

Apr 30, 2025
pulisher
Apr 30, 2025

Generac, Regulus Therapeutics, Garmin - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga

Apr 30, 2025
pulisher
Apr 30, 2025

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis By Stocktwits - Investing.com India

Apr 30, 2025
pulisher
Apr 30, 2025

Regulus Therapeutics' stock price doubles on Novartis's buyout offer - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

Regulus (RGLS) Downgraded Amid Acquisition Offer by Novartis | R - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Latham & Watkins Advises Regulus Therapeutics in Acquisition by Novartis AG - Latham & Watkins LLP

Apr 30, 2025
pulisher
Apr 30, 2025

Swiss pharma giant Novartis to acquire San Diego biotech Regulus in $1.7B deal - Axios

Apr 30, 2025
pulisher
Apr 30, 2025

Biotech Stock Soars Over 100% On Premarket Following Acquisition Announcement - The Globe and Mail

Apr 30, 2025
pulisher
Apr 30, 2025

Novartis to acquire Regulus Therapeutics for up to $1.7 billion - PharmaLive

Apr 30, 2025
pulisher
Apr 30, 2025

Regulus Announces Merger Agreement with Novartis - TipRanks

Apr 30, 2025

Regulus Therapeutics Inc (RGLS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
자본화:     |  볼륨(24시간):